Renalytix Stock
Renalytix Plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Country
- United Kingdom
- CEO
- James R. McCullough
- Employees
- 46
- Market cap
- £20 M
- IPO
- 06/11/2018
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such…
Renalytix stock: price history
1D
+0.0%
1W
+2.8%
1M
-12.8%
6M
+179.5%
YTD
-7.6%
1Y
-37.0%
2Y
-27.3%
5Y
-99.4%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~211% stronger price swings than usual
Ask the agents about Renalytix
Analyst assessment of Renalytix
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 29/06/2023
Renalytix stock metrics
P/E
-3.43
P/B
-23.15
EV/EBITDA
0
RETURN ON EQUITY
337.5%
NET MARGIN
-506.3%
DEBT/EQUITY
-4.83
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
62.1%
FLOAT SHARES
227,736,808
AVG. DAILY VOLUME (30D)
2,007,703
Comparable stocks
Frequently asked questions about Renalytix stock
What does Renalytix do?
Renalytix Plc is a company in the Healthcare sector, Medical - Healthcare Information Services industry, headquartered in United Kingdom.
The CEO is James R. McCullough, the company employs around 46 people.
The IPO was on 06/11/2018; the stock trades on LSE under the ticker RENX.L.
What do analysts say about Renalytix stock?
4 analysts rate the stock, the consensus is Buy (as of 29/06/2023).
This is an external assessment, not a statement by Market Jury.
When does Renalytix report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 211% stronger than usual.
Does Renalytix pay a dividend?
No, Renalytix currently does not pay a dividend.
Which stocks are comparable to Renalytix?
Comparable stocks include Optima Health, Hinge Health, HealthEquity, Heartflow, Omada Health, Teladoc Health, SOPHiA GENETICS and Evolent Health.
How can I get Renalytix stock analyzed?
Clicking "Analyze stock" lets five strategies assess Renalytix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.